The Larvol Group to Participate in the Pharma CI Conference

Online, September 10, 2012 (Newswire.com) - The new online platform offers increased functionality to clients including an online weekly news monitor, trial and milestone trackers, a conference tracker, an interactive heatmap and other customized analytics.

Company President, Bruno Larvol will also present at the conference, exploring the role that secondary sources play in advanced monitoring of news, conferences, analyst reports, trials and product milestones for the pharmaceutical industry. Mr. Larvol commented, "Pharma CI has always been an excellent opportunity for The Larvol Group to share recent product developments that enhance our clients' experience."

For more information regarding how The Larvol Group might be able to assist your organization, please visit our booth. Alternatively, if you would like to schedule a meeting with Bruno Larvol during the event, please contact Natalie Gulley at [email protected] at 512.426.1966.

The Larvol Group, LLC provides competitive intelligence tracking for the pharmaceutical industry. Our suite of subscription services includes customized brand-level, franchise-level, scientific and strategic monitoring.

The firm includes over 100 professionals worldwide
with a particular focus in oncology, CNS, diabetes
and inflammation as well as expertise in all major therapeutic areas. Our clients include 9 of the top 10 pharmaceutical companies.

About The Larvol Group:
The Larvol Group, LLC, (www.larvol.com) a San Francisco-based competitive intelligence company founded in 2004, provides innovative business intelligence services for the pharmaceutical industry. Their Market Intelligence Reports track relevant news, clinical trials and developments in the competitive landscape of a given indication. Drawing on the knowledge of over 100 professionals, The Larvol Group has expertise in all major therapeutic areas, including oncology, metabolic diseases, CNS, inflammation, cardiovascular, and pain management. Their diverse portfolio of clients includes top pharmaceutical companies and small to midsized biotech firms.